The identification of the SIRT1 activator SRT2104 as a clinical candidate

Letters in Drug Design and Discovery

Volumn 10, Issue 9, 2013, Pages 793-797

  Ng, Pui Yee ^a   Bemis, Jean E ^a   Disch, Jeremy S ^a   Vu, Chi B ^a   Oalmann, Christopher J ^a   Lynch, Amy V ^a   Carney, David P ^a   Riera, Thomas V ^a   Song, Jeffrey ^a   Smith, Jesse J ^a   Lavu, Siva ^a   Tornblom, Angela ^a   Duncan, Meghan ^a   Yeager, Marie ^a   Kriksciukaite, Kristina ^a   Gupta, Akanksha ^a   Suri, Vipin ^a   Elliot, Peter J ^a   Milne, Jill C ^a   Nunes, Joseph J ^a   Jirousek, Michael R ^a   Vlasuk, George P ^a   Ellis, James L ^a   Perni, Robert B ^a   more..

^a GLAXOSMITHKLINE   (United States)

Author keywords

Activator; Imidazothiazole; SIRT1; Sirtuin; SRT1720; SRT2104

Indexed keywords

DEXAMETHASONE; ENZYME ACTIVATOR; IMIDAZO[1,2 B]THIAZOLE; INTERLEUKIN 10; INTERLEUKIN 12P40; SIRTUIN 1; SRT 1720; SRT 2104; THIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RAT; STRUCTURE ACTIVITY RELATION;

EID: 84887936276     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/15701808113100990021     Document Type: Article

References (18)

1. Bauer, J. A.; Ungvari, Z.; Minor, R. K.; Le Couteur, D. G.; de Cabo, R. Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Disc., 2012, 11, 443-461.
2. Nakahata, Y.; Sahar, S.; Astarita, G.; Kaluzova, M.; Sassone-Corsi, P. Circadian control of the NAD+ salvage pathway by CLOCKSIRT1. Science, 2009, 324(5927), 654-657.
3. Oberdoerffer, P.; Michan, S.; McVay, M.; Mostoslavsky, R.; Vann, J.; Park, S. K.; Hartlerode, A.; Stegmuller, J.; Hafner, A.; Loerch, P.; Wright, S. M.; Mills, K. D.; Bonni, A.; Yankner, B. A.; Scully, R.; Prolla, T. A.; Alt, F. W.; Sinclair, D. A. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 2008, 135(5), 907-918.
4. Banks, A. S.; Kon, N.; Knight, C.; Matsumoto, M.; Gutierrez-Juarez, R.; Rossetti, L.; Gu, W.; Accili, D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 2008, 8(4), 333-341.
5. Yoshizaki, T.; Milne, J. C.; Imamura, T.; Schenk, S.; Sonoda, N.; Babendure, J. L.; Lu, J. C.; Smith, J. J.; Jirousek, M. R.; Olefsky, J. M. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol, 2009, 29(5), 1363-1374.
6. Gan, L.; Mucke, L. Paths of convergence: sirtuins in aging and neurodegeneration. Neuron, 2008, 58(1), 10-14.
7. Firestein, R.; Blander, G.; Michan, S.; Oberdoerffer, P.; Ogino, S.; Campbell, J.; Bhimavarapu, A.; Luikenhuis, S.; de Cabo, R.; Fuchs, C.; Hahn, W. C.; Guarente, L. P.; Sinclair, D. A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One, 2008, 3(4), e2020.
8. Bemis, J. E.; Vu, C. B.; Xie, R.; Nunes, J. J.; Ng, P. Y.; Disch, J. S.; Milne, J. C.; Carney, D. P.; Lynch, A. V.; Jin, L.; Smith, J. J.; Lavu, S.; Iffland, A.; Jirousek, M. R.; Perni, R. B. Discovery of oxazolo[ 4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg. Med. Chem. Lett., 2009, 19, 2350-2353.
9. Vu, C. B.; Bemis, J. E.; Disch, J. S.; Ng, P. Y.; Nunes, J. J.; Milne, J. C.; Carney, D. P.; Lynch, A. V.; Smith, J. J.; Lavu, S.; Lambert, P. D.; Gagne, D. J.; Jirousek, M. R.; Schenk, S.; Olefsky, J. M.; Perni, R. B. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem., 2009, 52, 1275-1283.
10. The methods for the preparation of each compound (4, 8-19) can be found in the Supplementary Material.
11. Pacholec, M.; Chrunyk, B. A.; Cunningham, D.; Flynn, D.; Griffith, D. A.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285(11), 8340-8351.
12. Dai, H.; Kustigian, L.; Carney, D.; Case, A.; Considine, T.; Hubbard, B. P.; Perni, R. B.; Riera, T. V.; Szczepankiewicz, B.; Vlasuk, G. P.; Stein, R. L. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem., 2010, 285, 32695-32703.
13. Hubbard, B. P.; Gomes, A. P.; Dai, H.; Li, J.; Case, A. W.; Considine, T.; Riera, T. V.; Lee, J. E.; Sook, Y. E.; Lamming, D. W.; Pentelute, B. L.; Schuman, E. R.; Stevens, L. A.; Ling, A. J. Y.; Armour, S. M.; Michan, S.; Zhao, H.; Jiang, Y.; Sweitzer, S. M.; Blum, C. A.; Disch, J. S.; Ng, P. Y.; Howitz, K. T.; Rolo, A. P.; Hamuro, Y.; Moss, J.; Perni, R. B.; Ellis, J. L.; Vlasuk, G. P.; Sinclair, D. A. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science, 2013, 339, 1216-1219.
14. Cell viability was assessed in primary human skeletal muscle myoblast cells (hSkMM) using Alamar Blue staining, which measures metabolic activity in the cell. LC50 was determined after a 24 h compound treatment.
15. Yang, H.; Zhang, W.; Pan, H.; Feldser, H. G.; Lainez, E.; Miller, C.; Leung, S.; Zhong, Z.; Zhao, H.; Sweitzer, S.; Considine, T.; Riera, T.; Suri, V.; White, B.; Ellis, J. L.; Vlasuk, G. P.; Loh, C. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kB activity. PLoS ONE, 2012, 7(9), e46364.
16. The results of the selectivity panel for SRT2104 can be found in the Supplementary Material.
17. Hoffmann, E.; Wald, J.; Lavu, S.; Roberts, J.; Beaumont, C.; Haddad, J.; Elliott, P.; Westphal, C.; Jacobson, E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br. J. Clin. Pharmacol., 2013, 75(1), 186-196.
18. Libri, V.; Brown, A. P.; Gambarota, G.; Haddad, J.; Shields, G. S.; Dawes, H.; Pinato, D. J.; Hoffman, E.; Elliot, P. J.; Vlasuk, G. P.; Jacobson, E.; Wilkins, M. R.; Matthews, P. M. A pilot randomized, placebo controlled, double blind Phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS ONE, 2012, 7(12), e51395.